In the Review by Maria Patricia Rivera, ‘Lung cancer in women: the differences in epidemiology, biology and treatment outcomes’, published in the December 2009 issue of Expert Review of Respiratory Medicine (Expert Rev. Resp. Med. 3[6], 627–634 [2009]), on page 629, the following sentence appeared as:
“While a decreased DNA repair capacity places women at increased risk for lung cancer, it also may play a role in improved survival, for as it turns out, owing to decreased DNA repair capacity, women with lung cancer may have better response and improved survival after treatment with platinum-based chemotherapy due to decreased levels of the DNA repair enzyme excision repair cross-complementation group 1 (ERCC1) Citation[1].”
The sentence should have read:
“While a decreased DNA repair capacity places women at increased risk for lung cancer, it is not clear if it also plays a role in improved survival. Although it has been reported that patients with lung cancers with low expression of the enzyme repair cross-complementation group 1 (ERCC1) have improved median survival following cisplatin and gemcitabine chemotherapy, no difference in ERCC1 levels between males and females with lung cancer has been reported Citation[1].”
The author and editors of Expert Review of Respiratory Medicine would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.
Reference
- Lord RV, Brabender J, Gandara D. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res.8, 2286–2291 (2002).